Re: Farmas USA
Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
http://investors.dynavax.com/news-releases/news-release-details/dynavaxs-sd-101-combi